ACTRN12606000405516尚未招募2 期
A phase II randomised, double-blind, placebo-controlled study of the effect of atorvastatin on postoperative renal function in patients undergoing elective cardiopulmonary bypass
Austin Hospital, Department of Intensive Care0 个研究点目标入组 102 人开始时间: 2006年9月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 102
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •1. Informed consent2. Elective cardiac surgery in males/females3. Planned cardiopulmonary bypass4. >1 risk factors for post-operative renal dysfunction.
排除标准
- •1. Emergent cardiac surgery, cardiac transplant or insertion of device2. Planned off-pump cardiac surgery3. Hypersensitivity, allergy or known intolerance to statins4. Pre-morbid end-stage kidney disease or renal transplant5. Pre-operative ARF, defined as an increase in serum creatinine ³88.4mmol/L (1.0mg/dL) from pre-admission to operation6. Active liver disease or cirrhosis7. Pre-operative unexplained elevation of serum transaminases8. Enrolled in a conflicting study9. Pregnancy10. Age below 18 years11. Pre-operative acute inflammation (e.g. endocarditis)12. Moderate to high-dose steroid therapy (e.g. >10mg prednisone or equivalent per day).
研究者
相似试验
进行中（未招募）
不适用
A research study to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25 µg, 2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in the evening in children 6 to 11 yrs old with asthma.Moderate persistent asthma in children 6 to 11 years oldMedDRA version: 14.1Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-022458-18-LVBoehringer Ingelheim Pharma GmbH & Co. KG104
进行中（未招募）
不适用
A research study to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25 µg, 2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in the evening in children 6 to 11 yrs old with asthma.Moderate persistent asthma in children 6 to 11 years oldMedDRA version: 14.1Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-022458-18-DEBoehringer Ingelheim Pharma GmbH & Co. KG104
进行中（未招募）
1 期
This study tests whether BI 409306 prevents patients with a specific type of mental illness (attenuated psychosis syndrome) from becoming worse. This study looks at how well patients tolerate the medicine and how safe and effective it is over 1 year.attenuated psychosis syndromeMedDRA version: 20.0 Level: LLT Classification code 10037234 Term: Psychosis System Organ Class: 100000004873EUCTR2016-004973-42-GBBoehringer Ingelheim Limited300
进行中（未招募）
1 期
This study tests whether BI 409306 prevents patients withschizophrenia from becoming worse. This study looks at how wellpatients tolerate BI 409306 and how effective it is over 6 monthsschizophreniaEUCTR2017-002369-23-ESBoehringer Ingelheim387
进行中（未招募）
不适用
A research study to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25 µg, 2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in the evening in children 6 to 11 yrs old with asthma.Moderate persistent asthma in children 6 to 11 years oldMedDRA version: 13.1Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-022458-18-HUBoehringer Ingelheim Pharma GmbH & Co. KG92